There is indirect evidence that unopposed human neutrophil elastase (HNE) is responsible for emphysema in patients with a1-proteinase inhibitor (Pi) deficiency. To directly explore this possibility, we developed an assay for fibrinopeptide and its degradation products and used it to measure HNE activity in 128 subjects of known Pi phenotype. The mean elastasespecific fibrinopeptide (ESF) level in 49 deficient PiZ individuals is significantly higher than that in 56 PiMZ heterozygotes (4.5 and 1.5 nM, respectively; P < 0.01), while the mean ESF value in heterozygotes is significantly elevated over that in 23 normal PiM subjects (1.5 and 0.6 nM, respectively; P < 0.01), consistent with increased HNE activity in those deficient in the major regulator of the enzyme. These results are not due to differences in smoking history because after correction for pack-years of smoking, ESF values in PiZ subjects are fourfold higher than those in PiMZ individuals (P = 0.005), while the ESF levels in heterozygotes are threefold higher than those in PiM subjects (P = 0.02). In addition, this analysis suggests that cigarette smoking and a1-proteinase inhibitor deficiency have additive effects on ESF levels thereby explaining why PiZ and some PiMZ individuals are at especially high risk for the development of lung disease if they smoke. Finally, the observation that ESF levels in nonsmoking PiZ subjects are inversely related to the percent of predicted forced expiratory volume in 1 s (FEV1%) provides direct support for the concept that unregulated HNE activity causes alveolar septal destruction in patients with a1-proteinase inhibitor deficiency. (J.
Introduction
Human neutrophil elastase (HNE)' has been implicated in the pathogenesis of a wide variety of diseases (1) . In particular, extracellular matrix injury resulting from the catalytic activity ofHNE may be the pivotal event in the pathogenesis ofpulmonary emphysema (2) . Support for this concept comes from two lines ofinvestigation. First, studies have demonstrated that congenital deficiency of a,-proteinase inhibitor, the major plasma regulator of HNE (3), is associated with the early development of severe, panlobular emphysema (4) . Second, several investigators have shown that the intrapulmonary instillation ofHNE into experimental animals leads to anatomic derangements in lung architecture with the characteristics of human emphysema (5, 6) . These observations have led to the proposal that unregulated HNE activity in the lungs is responsible for the alveolar septal destruction that occurs in patients with a,-proteinase inhibitor deficiency.
In the past, it has been difficult to evaluate HNE activity in vivo because the enzyme rapidly binds to its substrates or its inhibitors (3) , and because pathogenetically important HNE activity may be confined to localized microenvironments within tissues (7) (8) (9) (10) (11) (12) (13) (14) (15) . Recently, we have developed an assay for in vivo HNE activity based on the unique capacity of the enzyme to cleave the Aa2 1 (Val)-Aa22 (Glu) bond on the aminoterminal region of the Aa-chain of fibrinogen (16) . Hydrolysis of this bond results in release of the fibrinopeptide A-containing fragment Aa 1-21. The original radioimmunoassay for the quantification of Aa 1-21 was indirect (17) , and used a specific antiserum against fibrinopeptide A (FPA or Aa [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . This antiserum has its antigenic determinant at the carboxy-terminal region ofthe FPA molecule (17) (18) (19) (20) . Since this epitope is inaccessible in larger FPA-containing fragments, the antibody reacts poorly with Aa 1-21 (16, 20) . When Aa 1-2 1-containing samples are incubated in vitro with thrombin, however, the FPA portion of the peptide is released. This results in an 1 l,000-fold increase in immunoreactivity (20) which we designated thrombin-increasable FPA immunoreactivity (TIFPA) (16) .
Using plasma levels of TIFPA as an index of in vivo HNE activity, higher peptide values were found in cigarette smokers than in nonsmokers (21) . Further, individuals with congenital deficiency of a,-proteinase inhibitor had plasma levels of TIFPA considerably higher than those in smokers (16, 21) . The purpose of this study was to extend these observations in two ways. First, we set out to develop a specific assay for Aa 1-21 to obviate the need for in vitro treatment of the plasma samples with thrombin. Second, using this test as an index of unopposed HNE activity, we set out: (a) to compare the effect of cigarette smoking on HNE activity in subjects with congenital deficiency of a I-proteinase inhibitor (phenotype PiZ) with that in heterozygotes (type PiMZ) and in normals (type PiM); and (b) to explore directly the link between unregulated enzyme activity and lung destruction in PiZ individuals.
Methods
Reagents. Human a-thrombin (sp act 2,850 U/mg) was generously provided by Dr (Pierce) , was then used to couple the amino-terminal cysteine residue of this peptide to Keyhole Limpet hemocyanin. As another immunogen, synthetic Aal-20 was coupled to BSA (crystallized, grade V; Sigma Chemical Co.) using the glutaraldehyde method previously described for the conjugation of FPA (24) .
Immunization procedure. The immunogens were suspended in 0.9% sterile NaCl at a concentration of 1 mg/ml and vortexed thoroughly with three parts ofcomplete (primary immunization) or incomplete (booster immunizations) Freund's adjuvant (Calbiochem-Behring Corp., San Diego, CA) until a thick emulsion formed. Four sheep were each immunized with 500 jig of the AaC14-21 derivative using the multiple intradermal injection technique (25) . Booster immunizations consisting of 500 ,g of immunogen were given intramuscularly every 3 wk thereafter, and the animals were bled at the same time. Four white male New Zealand rabbits were each immunized with 200 ,g of the Aa 1-20 conjugate again using the multiple intradermal injection technique (25) . 10 wk after primary immunization, each rabbit was given 100 ,ug of immunogen intramuscularly into the haunches. Blood was collected at 8 wk, and every 2 wk thereafter.
Radioimmunoassays. TIFPA was assayed as previously described (16) using antiserum R2. This antibody is specific for FPA and crossreacts poorly with fibrinogen or FPA-containing fragments (17) (18) (19) (20) (-15 ,000 cpm/tube).
After 18 h incubation at 4VC, tracer bound to antibody was precipitated using rabbit anti-sheep or goat anti-rabbit IgG (Sigma) in quantities sufficient to bind all ofthe sheep or rabbit IgG, respectively. In each case, the second antibody was diluted in TBS containing 20 mg/ml polyethylene glycol 8,000 (Fisher Scientific Co., Pittsburgh, PA). The tubes were then incubated for 30 min at 230C, diluted with 2 ml of 0.9% NaCl, and centrifuged at 4,000 g for 20 min at 40C. The supernatant fluid was aspirated and the pellets were counted for 1 min using a Clinigamma counter (LKB Instruments, Gaithersburg, MD).
Stability ofAal-21 immunoreactivity. The stability of Aal-21 immunoreactivity was determined in whole blood and in plasma. Using a 2 1-gauge butterfly needle, blood was collected from the antecubital veins of healthy volunteers into 10-ml vacutainer tubes (Becton Dickinson & Co., Mountain View, CA) prefilled with 1 ml of anticoagulant solution consisting of 1,000 kallikrein inhibitor units (KIU)/ml aprotinin, 1,400 U/ml heparin, and 0.1 mM MeO-Suc-Ala2-Pro-ValCH2Cl in Hepes-buffered saline, pH 7.4. After mixing with the anticoagulant, the blood was either used directly or cell-free plasma was prepared by centrifugation at 2,000 g for 15 min at 40C. Synthetic Aal-21 (20 pmol/ml) was then incubated in 2-ml aliquots of blood or plasma for 60 min at 370C in the presence or absence of o-phenanthroline (final concentration, 10 mM). At intervals, 200-id aliquots were removed, and fibrinogen was precipitated by the addition of 600 ul of chilled ethanol followed by centrifugation at 15,000 g for 5 min. The ethanol supernatants were then evaporated to dryness in a Speed-Vac concentrator (Savant Instruments, Inc., Hicksville, NY) and reconstituted to original volume with distilled water. The levels of AaC1-21 were then quantified using the three assays described above.
Effect ofcarboxypeptidases on Aal-21 immunoreactivity in buffer. Synthetic Aa 1-2 1, suspended in TBS at a concentration of20 nM, was incubated for 60 min at 37°C in the presence or absence ofcarboxypeptidases A, B, or Y (at concentrations ranging from 0.01 to 10.0 U/ml).
At intervals, 200-,gl aliquots were removed, the reaction was terminated by the addition of o-phenanthroline (final concentration, 10 mM), and the levels of Aal-2 1 were then quantified using the three assays described above.
HPLC analysis ofcarboxypeptidase-mediated proteolysis ofAal- 21 . The time course of carboxypeptidase-mediated proteolysis ofAal-21 also was monitored using reversed-phase HPLC. Aa 1-21 was suspended in TBS at a concentration of 1.0 mg/ml. 1-ml aliquots were then incubated for 3 h at 37°C with carboxypeptidases A, B, or Y (at concentrations ranging from 0.01 to 10.0 U/ml). At intervals, 100-Ml aliquots were removed, and the reaction was terminated by lowering the pH to 2.1 by the addition of0.1% trifluoroacetic acid. After passage over Sep-Pak C 18 cartridges (Waters Associates, Millipore Corp., Milford, MA), adsorbed peptides were eluted with 3 ml of50% acetonitrile, evaporated to dryness in a Speed-Vac concentrator, and then reconstituted to original volume with 0.1% trifluoroacetic acid before HPLC analysis.
Analytical HPLC was performed using a liquid chromatograph (System Gold; Beckman Instruments Inc., Palo Alto, CA) equipped with two model 126 solvent delivery systems, and a model 506 automatic injector. Peptides were monitored using a model 167 variable wave length absorbance detector set at 214 nm. The column used for these studies was an Ultrasphere ODS C18 (4.6 mm i.d., Beckman Instruments). Solvents used in the chromatography were 0.1% trifluoroacetic acid (buffer A), and 0.1% trifluoroacetic acid containing 50% acetonitrile (buffer B). Using a flow rate of 1 ml/min, peptides were eluted from the column with a linear gradient constructed from buffers A and B, and extending from 30 to 70% buffer B over 30 min. 1-ml fractions were collected, evaporated to dryness in a Speed-Vac concentrator (Savant Instruments), and reconstituted with 500 ,l of distilled water. The levels ofAa were then quantified using the three assays described above.
Clearance ofAal-21 in marmosets. Synthetic human Aal-21 was injected intravenously into four marmosets (Callithrix jacchus jacchus), and the disappearance of Aa1-21 immunoreactivity was then determined using the three assays described above. After anesthetizing the animals with an intramuscular injection of ketamine (0.5 mg/kg), the femoral vein was exposed, and a 21-gauge catheter fitted with a two-way stopcock was inserted into the vein and held in place with a suture. Blood samples were taken before, and at intervals after, bolus intravenous injection of Ac 1-21 (1 mg/kg), while patency of the catheter was maintained by infusing 0.5 ml of 0.9% NaCl containing I U/ml heparin after each blood sample was collected. At each time point, 900 ,l ofblood was collected into a plastic syringe, and immediately transferred into a polypropylene Eppendorf tube prefilled with 100 ,l of anticoagulant solution consisting of aprotinin, heparin, and MeO-Suc-Ala2-Pro-ValCH2Cl in the concentrations listed above. After mixing the blood with the anticoagulant, the red cells were sedimented by centrifugation at 15,000 g for 5 min, 300 ,l of plasma was removed, and the fibrinogen was precipitated by the addition of 900 Ml of chilled ethanol followed by centrifugation at 15,000 g for 5 min. The ethanol supernatants were evaporated to dryness in a Speed-vac concentrator (Savant Instruments), reconstituted to original volume with ethanol, and the levels of Aal-2 1 were then quantified using the three assays described above.
Plasma peptide levels in subjects with known at,-proteinase inhibitor (Pi) phenotype. Blood samples were collected from subjects with a,-proteinase inhibitor deficiency oftype PiZ, from their first-degree relatives, and from an additional control population with the normal (PiM) phenotype. The Pi type of each individual was determined by isoelectric focusing of dithioerythritol-treated serum on polyacrylamide gels at pH 4.2-4.9 (27, 28) . Probands with at-proteinase inhibitor deficiency (type PiZ) were the first 50 subjects recruited for a genetic epidemiologic study aimed at investigating the variable expression of lung disease in this patient group, and their clinical features and means of ascertainment have been described in detail by Silverman et al. (29, 30) . In addition, 71 first-degree relatives of these subjects also were investigated. Of these, 56 were heterozygotes (type PiMZ), while 15 had a normal phenotype (type PiM). A further control population of 8 healthy unrelated PiM individuals also was included. All individuals underwent pulmonary function testing using the previously described methods (29) . In addition, smoking history was obtained from a modified version of the ATS-DLD-78 respiratory epidemiology questionnaire (31) , and the serum concentrations of al-proteinase inhibitor were determined by particle-concentration fluorescence immunoassay as we have described (30, 32) . This study was approved by the Institutional Review Board of the Jewish Hospital of St. Louis, MO.
After informed consent was obtained from each subject, blood was collected into 10-ml siliconized vacutainer tubes (Becton Dickinson) prefilled with 1 ml of anticoagulant solution consisting of 1,400 U/ml heparin, 1,000 KIU/ml aprotinin, and 0.1 mM MeO-Suc-Ala2-ProValCH2Cl in Hepes-buffered saline, pH 7.4. Extreme care was taken in blood collection and processing to ensure consistent and reliable assay results. After centrifugation at 1,700 g for 15 min at 4°C, 4 ml of plasma was carefully removed. Fibrinogen was precipitated by the addition of 12 ml of chilled ethanol followed by centrifugation at 4,000 g for 20 min at 4°C. The ethanol supernatants were evaporated to dryness in a Speed-vac concentrator (Savant Instruments) and reconstituted to original volume with distilled water. The levels ofAal-21 were then quantified using the three assays described above. For crI-proteinase inhibitor measurements, serum obtained from the same phlebotomy was stored at -90°C until analyzed.
Statistical methods. Since plasma peptides levels are log normally distributed, geometric means were calculated and all analyses were performed on log transformed data. The significance of differences was determined by analysis of variance or covariance and Tukey Studentized t tests using the SAS statistical package for the personal computer (SAS Statistical Institute, Cary, NC) on an IBM PS/2 Model 80 computer.
Results
Characterization ofantisera. Three of four sheep injected with the Ac 14-21 homologue produced antibodies. One antiserum, designated S-847, showed the highest titer, and was used in these studies. This antiserum is specific for Aa 1-21 and does not cross-react with FPA or larger FPA-containing fragments (Table I ). The carboxy-terminal Val residue of Aa 1-21 is a critical element of the epitope for S-847 since the antiserum does not recognize FPA-containing fragments shorter than Aal1-21 (i.e., Aa 1-20, Aa l-19, and Aal-18).
All four rabbits immunized with Aa 1-20 produced antibodies, and the antiserum with the highest titer, designated antiserum R20, was chosen for further study. This antiserum crossreacts completely with Aa 1-21, Ac 1-20, and Aa 1-19, but does not react with the larger FPA-containing fragments Aa 1-23 and Aa 1-27 (Table I) . Although Aa 1-18 also is recognized, R20 is virtually nonreactive with FPA or its homologues. These findings indicate that the antigenic determinant for R20 is at the carboxy-terminal region of the Aa 1-20 fragment.
Comparison of plasma Aa1-21 levels measured with the three different assays. Using antiserum S-847, a radioimmunoassay specific for Aa 1-21 was developed. The levels of Aca 1-21 measured with this assay were then compared with TIFPA values in plasma samples collected from 30 subjects with a variety of clinical disorders. As illustrated in Fig. 1 A, the levels of Aa 1-21 are considerably lower than the TIFPA values, and comparison of the results of the two assays using paired t tests demonstrates a highly significant difference between the two tests (P < 0.0005). Antiserum R20 also was used for the development of a radioimmunoassay. In addition to measuring Aa 1-21, this assay also recognizes smaller FPA-containing fragments (designated elastase-specific fibrinopeptides or ESF for reasons outlined below). In contrast to the results obtained with the specific Aa 1-21 assay (Fig. 1 A) , there is a good correlation between the TIFPA and ESF assays (Fig. 1 B) . When (Table I) , these data explain the more rapid loss ofAa immunoreactivity when the peptide is quantified using the assay specific for Aa 1-21. Further, these findings indicate that the sequence of degradation of Aa1-21 in vivo is identical to that produced in vitro by carboxypeptidases A, B, or Y.
ESF levels in subjects ofknown Pi phenotype. To examine the correlation between plasma ESF levels and Pi phenotype, a total of 128 subjects of known a1-proteinase inhibitor phenotype was investigated (Fig. 4) . The mean ESF level in PiZ individuals is significantly elevated over that in heterozygotes with the PiMZ phenotype (4.5 and 1.5 nM, respectively; P < 0.01). In addition, the mean ESF value in heterozygotes is significantly higher than that in subjects with the normal PiM pheno- (21), part ofthe observed effect of Pi phenotype on ESF values may reflect differences in smoking history. To investigate this possibility in current smokers, analysis of covariance was performed to provide an estimate of the effect of Pi phenotype on plasma ESF levels which was then adjusted for differences in smoking history. The results of this analysis are illustrated in Fig. 5 , in which the ESF values for each phenotypic group are plotted against pack-years of cigarette smoking. This model indicates a common trend of increasing ESF values with greater pack-years of smoking. In addition, however, there is a distinct separation (P < 0.0001) in the position (i.e., the intercept) of the relationship for each phenotype group. This vertical separation represents the influence of phenotype independent of the effect of cigarette smoking, and indicates a threefold increase in ESF levels in PiMZ subjects as compared to PiM individuals (P = 0.02), and a further fourfold elevation in ESF values in PiZ subjects as compared to PiMZ individuals (P = 0.005). Thus, this analysis demonstrates that the relationship between ESF levels and Pi phenotype that is illustrated in Fig. 4 is not the result of differences in smoking history but is caused by differences in the concentrations of a,-antiproteinase inhibitor. This concept is further supported by the observation that the plasma ESF levels show a significant inverse relationship with the serum levels of a,-proteinase inhibitor (P < 0.001), indicating increased HNE activity in those individuals deficient in the major regulator of the enzyme.
To test the concept that there is a link between unopposed HNE activity and lung dysfunction, plasma ESF values in 12 lifelong nonsmoking PiZ subjects were plotted as a function of the percent of predicted forced expiratory volume in 1 s (FEV,%). The data on the 27 ex-smokers and 10 current smokers in the PiZ group were excluded from this analysis because cigarette smoking can directly elevate peptide levels (21) , and can in itself lead to lung dysfunction (33). As shown in Fig. 6 in the population described above, selected samples also were analyzed by HPLC using a gradient that separates Aa 1-21 from its carboxypeptidase-derived degradation products (Fig. 7) . Fractions were collected and assayed for TIFPA and ESF. (Table I) , peptide levels are not significantly different from those obtained with the TIFPA assay (Fig. 1 B) . In contrast, the results obtained with antiserum S-847, which only measures intact Aa 1-21 (Table I) , are considerably lower than those obtained with the TIFPA assay (Fig. 1  A) . This discrepancy reflects degradation of Aal-21 into fragments that are not recognized by antiserum S-847 because the incubation of Aa 1-21 in blood results in rapid and progressive loss of immunoreactivity which is blocked by the addition of o-phenanthroline (Fig. 2 A) . Further, incubation of Aa 1-21 with carboxypeptidases A, B, or Y results in a similar loss of immunoreactivity ( Fig. 2 B) , and HPLC analysis of the timecourses of Aai -21 proteolysis indicates that these carboxypeptides progressively degrade Aa 1-21 first to Aa 1-20, and then to Aa 1-19 (Fig. 3) . The finding that all three carboxypeptidases produce the same pattern of Aa 1-21 degradation can be explained on the basis of the specificities of these enzymes. Carboxypeptidase Y does not cleave a carboxy-terminal Arg residue, thus accounting for the stability of the Aal-19 fragment (34). In contrast, carboxypeptidases A and B do not further degrade Aa1-19 because the Pro residue at position 18 makes the Arg residue at the carboxy-terminal of Aa1-19 an unfavorable site for further proteolysis (35, 36) .
Two lines of evidence indicate that proteolysis of Aa 1-21 by carboxypeptidase-like activity also occurs in vivo. First, clearance studies in nonhuman primates demonstrate that Aa 1-21 immunoreactivity disappears almost twofold faster when the peptide is quantified with the specific assay for Aa1-21 than when it is measured using the ESF or TIFPA assay, and HPLC analysis of these samples indicates that this difference is due to the rapid conversion of the injected Aa 1-21 to Aa 1-20 and Aa1-19. Second, HPLC analysis ofpatient samples demonstrates that most of the ESF or TIFPA immunoreactivity coelutes with Aa 1-19 and Aa 1-20, while only a small fraction coelutes with intact Aa 1-21 (Fig. 7) . Although our previous HPLC studies suggested that TIFPA immunoreactivity coeluted with Aa 1-21 (16, 21) , the gradient used in those investigations does not adequately separate Aa 1-21 from Aa 1-20 and Aal -19, thus accounting for this discrepancy.
Carboxypeptidase-mediated proteolysisofotherfibrinopeptides has been well described. Both the thrombin-derived frag- (39) , suggesting that this process may not alter the biologic activity of these peptides.
Having developed and validated the direct assay for ESF both in vitro and in vivo, we used this test as an index of HNE activity in individuals of known phenotype for a1-proteinase inhibitor (Fig. 4) . The increased ESF levels in PiZ subjects with marked deficiency ofthe major regulator ofHNE are not unexpected since these findings are consistent with our previous observations in this phenotypic group (16) . Although there has been indirect evidence that unopposed HNE activity is responsible for the early onset ofemphysema in PiZ individuals (1, 2, 4, 5), the inverse relationship between plasma ESF levels and FEV1% in nonsmoking PiZ individuals (Fig. 6 ) provides direct support for the concept that unregulated HNE activity causes alveolar septal destruction in patients with a I-proteinase inhibitor deficiency.
The presence of circulating ESF in PiM individuals with normal concentrations of a1-proteinase inhibitor, and the higher values in PiMZ heterzygotes who have only a modest decrease in inhibitor levels, would not be predicted given the rapidity with which a1-proteinase inhibitor complexes and inactivates free HNE (3, 40, 41) . However, a plausible explanation for the measurable ESF levels in control subjects is provided by our recent studies of neutrophils migrating on a fibrinogen-coated surface in response to the chemoattractant FMLP. Upon stimulation, the neutrophils degrade extracellular fibrinogen and release Aa 1-21 despite the presence ofphysiologic concentrations of macromolecular proteinase inhibitors (1 1). This phenomenon occurs because zones of close contact are formed between the neutrophils and the fibrinogen which prevent access of plasma antiproteinases to HNE released at the cell-substrate interface. Further investigations have demonstrated that the interaction between neutrophils and fibrinogen is mediated by the complement receptor type 3 (CR3; Cdl lb/ Cdl 8) on neutrophils which ligates fibrinogen through a discrete domain located on the carboxy-terminus of its gammachains (42) .
The finding that ESF values in PiMZ heterozygotes are higher than those in PiM controls suggests that in addition to exclusion of antiproteinases from sites of cell contact with fibrinogen, there must be other mechanisms of HNE-mediated proteolysis that are critically dependent on the circulating levels of a,-proteinase inhibitor. Support for this concept comes from the results of in vitro studies which demonstrate that the inactivation of HNE in the pericellular microenvironment of neutrophils and monocytes requires substantially higher concentrations of aI-proteinase inhibitor than those needed to inactivate free enzyme (7) (8) (9) (10) (11) (12) (13) (14) (15) . These findings have led to the suggestion that the proteolytic activity of HNE is confined to the vicinity ofinflammatory cells. Inactivation ofHNE at these sites requires more inhibitor both because the local concentration of enzyme is very high on or near the cell surface (43) , and because cellular oxidants inactivate a I-proteinase inhibitor (9) . Based on this model, even a minor reduction in the serum concentration ofa I-proteinase inhibitor will result in increased HNE-mediated proteolysis.
Although cigarette smoking can directly influence plasma ESF levels (21), the correlation between peptide values and Pi phenotype is not the result of differences in smoking history.
Analysis of covariance demonstrates highly significant differences for each phenotypic group that are independent of the pack-years of smoking (Fig. 5) . Thus, this analysis supports the concept that cigarette smoking and a,-proteinase deficiency have additive effects on HNE activity. Because subjects with a,-proteinase inhibitor deficiency have ESF levels higher than those in normals, the additive effect of cigarette smoking is potentially more dangerous in these patients. These findings may explain why PiZ and some PiMZ subjects are at especially high risk for lung disease if they smoke (29, 30, (44) (45) (46) .
There are many potential mechanisms by which cigarette smoking can increase HNE activity. Several lines of evidence indicate that cigarette smokers have increased neutrophil traffic through the lungs. Thus, cigarette smoking delays neutrophil transit through the pulmonary circulation (47) , and increased numbers of neutrophils are recovered in the bronchial lavage fluid ofsmokers (48) . Further, these migrating cells have the potential to produce more HNE-mediated damage because cigarette smoke promotes enzyme release from the neutrophils (49) , and oxidatively inactivates a,-proteinase inhibitor (50, 51). These findings may explain why ESF levels are higher in cigarette smokers (21) , and why the effect of smoking on peptide levels may be greater in individuals deficient in a,-proteinase inhibitor (Fig. 5) . Thus, our present results directly support the concept that cigarette smoking and a1-proteinase inhibitor deficiency interact to facilitate alveolar septal destruction.
